Fri, Sep 19, 2014, 1:56 AM EDT - U.S. Markets open in 7 hrs 34 mins


% | $
Quotes you view appear here for quick access.


  • lastbullstanding lastbullstanding May 3, 2013 10:14 AM Flag

    Is ACTC the first mouse?

    We all know the theory behind the first mouse and the cheese.

    Lanza is a stem cell guy,not an eye guy. When ya look at the big wig eye guys and their approach the consenus is really to lay the cells down on a substrate. Lanza even admitted in an interview that they would need a contigency plan (biotech in a blink ) .

    New improved methods to lay those substrates down in a less invasive way are being discovered.. Coffey although way behind in effect has allowed ACTC to help shine the light on the safety issues. Will essentially a fabricated Bruch turn out to be a more effective method. Who will lead the way? Riken is probably the powerhouse. Or does RPE itself just take the back burner and photoreceptors are really the ticket.

    Odds are this first program of ACTC's will not be make it to market. It will however have helped pave the way to the ultimate success of stem cells and the eyes.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.08150.0000(0.00%)Aug 27 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Oracle Corporation
NYSEThu, Sep 18, 2014 4:04 PM EDT
Concur Technologies, Inc.
NasdaqGSThu, Sep 18, 2014 4:00 PM EDT